The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells
暂无分享,去创建一个
M. Ciccozzi | M. Giovanetti | C. Ravelli | A. Bugatti | A. Caruso | F. Caccuri | A. Zani | Federica Filippini | Serena Messali
[1] R. Podgornik,et al. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron Mutations on Therapeutic Monoclonal Antibodies , 2022, bioRxiv.
[2] A. Caruso,et al. Endothelial cells are major players in SARS-CoV-2-related acute respiratory distress syndrome , 2022, eBioMedicine.
[3] C. Garlanda,et al. Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 , 2022, Frontiers in Immunology.
[4] S. Rong,et al. Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate , 2022, Scientific Reports.
[5] M. Karsdal,et al. The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling , 2022, eBioMedicine.
[6] Hossein Estiri,et al. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England , 2022, JAMA network open.
[7] R. Gómez,et al. Proteomic Analysis Identifies Molecular Players and Biological Processes Specific to SARS-CoV-2 Exposure in Endothelial Cells , 2022, International journal of molecular sciences.
[8] D. Ueno,et al. Senescent endothelial cells are predisposed to SARS-CoV-2 infection and subsequent endothelial dysfunction , 2022, Scientific Reports.
[9] Qian Wang,et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.
[10] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[11] Arvind H. Patel,et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein , 2022, bioRxiv.
[12] D. Jonigk,et al. Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19. , 2022, Cold Spring Harbor perspectives in medicine.
[13] E. Belley‐Cote,et al. Venous and arterial thrombosis in COVID-19: An updated narrative review , 2022, Journal of Infection and Public Health.
[14] P. Chiodelli,et al. SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies , 2022, Viruses.
[15] P. Boor,et al. INFLAMMATION AND VASCULAR REMODELING IN COVID-19 HEARTS , 2022, Journal of the American College of Cardiology.
[16] D. Scheim. A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody , 2022, International journal of molecular sciences.
[17] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[18] W. Hanage,et al. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. , 2022, The New England journal of medicine.
[19] L. Poon,et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.
[20] N. Rahimi,et al. Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells , 2022, Proceedings of the National Academy of Sciences.
[21] Peng Sun,et al. Cardiovascular Risk After SARS-CoV-2 Infection Is Mediated by IL18/IL18R1/HIF-1 Signaling Pathway Axis , 2022, Frontiers in Immunology.
[22] I. Douglas,et al. Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19 , 2021, JAMA network open.
[23] D. Easton,et al. Covid-19 Vaccine Effectiveness in New York State , 2021, The New England journal of medicine.
[24] S. Hsu,et al. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2 , 2021, Nature Chemical Biology.
[25] C. Clapp,et al. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling , 2021, bioRxiv.
[26] Jinrong Fu,et al. The signal pathways and treatment of cytokine storm in COVID-19 , 2021, Signal Transduction and Targeted Therapy.
[27] L. Dölken,et al. SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro , 2021, Frontiers in Cellular and Infection Microbiology.
[28] F. Facchetti,et al. SARS-CoV-2 Infection Remodels the Phenotype and Promotes Angiogenesis of Primary Human Lung Endothelial Cells , 2021, Microorganisms.
[29] N. Fletcher,et al. SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19 , 2021, PloS one.
[30] N. Banholzer,et al. Estimating the effects of non-pharmaceutical interventions on the number of new infections with COVID-19 during the first epidemic wave , 2021, medRxiv.
[31] A. Moreau,et al. High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19 , 2021, Infectious Diseases Now.
[32] J. Haas,et al. Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells , 2021, Circulation.
[33] K. Schroder,et al. Endothelial cells are not productively infected by SARS‐CoV‐2 , 2021, Clinical & translational immunology.
[34] V. Ferrer,et al. Endothelial cells and SARS-CoV-2: An intimate relationship , 2020, Vascular Pharmacology.
[35] T. Hobman,et al. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 , 2020, Viruses.
[36] L. Rénia,et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation , 2020, medRxiv.
[37] E. Mackow,et al. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses , 2020, bioRxiv.
[38] P. Sorger,et al. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques , 2020, Cell.
[39] J. P. de Rivero Vaccari,et al. The Inflammasome in Times of COVID-19 , 2020, Frontiers in Immunology.
[40] P. Venkatesan. The changing demographics of COVID-19 , 2020, The Lancet Respiratory Medicine.
[41] G. Curley,et al. A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets? , 2020, Drug Discovery Today.
[42] M. Ciccozzi,et al. A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual , 2020, Journal of translational medicine.
[43] L. Alberghina,et al. Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro” , 2020, Journal of medical virology.
[44] G. Guyatt,et al. A living WHO guideline on drugs for covid-19 , 2020, BMJ.
[45] P. Anyfanti,et al. Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses , 2020, Current Hypertension Reports.
[46] P. Libby,et al. COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.
[47] C. Cheung,et al. Vascular underpinning of COVID-19 , 2020, Open Biology.
[48] William E. Arter,et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? , 2020, Clinical medicine.
[49] H. Krumholz,et al. Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.
[50] C. Peano,et al. Macropahge expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, medRxiv.
[51] Duc-Huy T. Nguyen,et al. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids , 2020, Cell Stem Cell.
[52] F. Potus,et al. Novel insights on the pulmonary vascular consequences of COVID-19 , 2020, American journal of physiology. Lung cellular and molecular physiology.
[53] É. Azoulay,et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection , 2020, Critical Care.
[54] Guohui Wan,et al. New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection , 2020, Frontiers in Pharmacology.
[55] A. Huisman,et al. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS‐CoV‐2 , 2020, International journal of laboratory hematology.
[56] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[57] M. Hollinshead,et al. Electron microscopic investigations in COVID-19: not all crowns are coronas , 2020, Kidney International.
[58] P. Carmeliet,et al. COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.
[59] A. Osterhaus,et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19) , 2020, The Journal of pathology.
[60] J. Bartholomew,et al. Coagulopathy in COVID-19. , 2020, Cleveland Clinic journal of medicine.
[61] D. Alsteens,et al. Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans. , 2020, Annual review of virology.
[62] John T Brooks,et al. Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic , 2020, Emerging infectious diseases.
[63] Sara E. Miller,et al. Electron microscopy of SARS-CoV-2: a challenging task , 2020, The Lancet.
[64] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[65] Niema Moshiri,et al. ViralMSA: Massively scalable reference-guided multiple sequence alignment of viral genomes , 2020, bioRxiv.
[66] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[67] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[68] Ruiyun Li,et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) , 2020, Science.
[69] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[70] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[71] Olga Chernomor,et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.
[72] Heng Li,et al. Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..
[73] Trevor Bedford,et al. Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.
[74] Richard A Neher,et al. TreeTime: Maximum-likelihood phylodynamic analysis , 2017, bioRxiv.
[75] Yuelong Shu,et al. GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[76] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[77] P. Sagulenko. Maximum likelihood phylodynamic analysis , 2017 .
[78] V. Frémeaux-Bacchi,et al. Endothelial cells: source, barrier, and target of defensive mediators , 2016, Immunological reviews.
[79] M. Balaan,et al. Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.
[80] T. Stehle,et al. Glycan Engagement by Viruses: Receptor Switches and Specificity. , 2014, Annual review of virology.
[81] M. Slevin,et al. HIV-1 Matrix Protein p17 Promotes Lymphangiogenesis and Activates the Endothelin-1/Endothelin B Receptor Axis , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[82] M. Rusnati,et al. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. , 2009, Current pharmaceutical design.
[83] H Lortat-Jacob,et al. Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat* , 2001, The Journal of Biological Chemistry.